During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer research were presented. VJOncology has brought together a panel of leading GU experts to consider and debate the latest developments in bladder and kidney cancer and offer their perspectives on how they could impact patient care in the future.

This post-ASCO GU cancer roundtable discussion is chaired by Elizabeth Plimack, MD, MS, from the Fox Chase Cancer Center, Philadelphia, PA, who is joined by  Rana McKay, MD, University of California San Diego, San Diego, CA, and Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK.

Listen to this podcast to learn about the latest research in immunotherapy for the treatment of muscle-invasive bladder cancer and the exciting recent developments in bladder-sparing approaches. The panel also discuss groundbreaking adjuvant pembrolizumab data from KEYNOTE-564 in renal cell carcinoma (RCC) and how it will change their clinical practice in the future. In addition, we hear about updated results from the CLEAR trial, KEYNOTE-426, as well as alternative approaches in treating advanced RCC such as using the probiotic CBM588 in conjunction with immunotherapy.